119 related articles for article (PubMed ID: 38000292)
21. Anlotinib suppressed tumor cell proliferation and migration in hypopharyngeal carcinoma.
Song H; Song Q; Zhao X; Yang Y; Mou Y; Li Y; Song X
Braz J Otorhinolaryngol; 2024; 90(2):101397. PubMed ID: 38330738
[TBL] [Abstract][Full Text] [Related]
22. The role of Aurora A in hypoxia-inducible factor 1α-promoting malignant phenotypes of hepatocelluar carcinoma.
Cui SY; Huang JY; Chen YT; Song HZ; Huang GC; De W; Wang R; Chen LB
Cell Cycle; 2013 Sep; 12(17):2849-66. PubMed ID: 23966163
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of anlotinib, a multikinase angiogenesis inhibitor, in combination with epirubicin in preclinical models of soft tissue sarcoma.
Wang ZM; Zhang SL; Yang H; Zhuang RY; Guo X; Tong HX; Zhang Y; Lu WQ; Zhou YH
Cancer Med; 2020 May; 9(10):3344-3352. PubMed ID: 32181596
[TBL] [Abstract][Full Text] [Related]
24. Revealing the suppressive role of protein kinase C delta and p38 mitogen-activated protein kinase (MAPK)/NF-κB axis associates with lenvatinib-inhibited progression in hepatocellular carcinoma in vitro and in vivo.
Wu CH; Hsu FT; Chao TL; Lee YH; Kuo YC
Biomed Pharmacother; 2022 Jan; 145():112437. PubMed ID: 34864311
[TBL] [Abstract][Full Text] [Related]
25. MicroRNA-6077 enhances the sensitivity of patients-derived lung adenocarcinoma cells to anlotinib by repressing the activation of glucose transporter 1 pathway.
Ma DB; Qin MM; Shi L; Ding XM
Cell Signal; 2019 Dec; 64():109391. PubMed ID: 31421224
[TBL] [Abstract][Full Text] [Related]
26. Antitumor effects of anlotinib in thyroid cancer.
Ruan X; Shi X; Dong Q; Yu Y; Hou X; Song X; Wei X; Chen L; Gao M
Endocr Relat Cancer; 2019 Jan; 26(1):153-164. PubMed ID: 30139768
[TBL] [Abstract][Full Text] [Related]
27. Anlotinib plus Sintilimab achieved in an antitumor effect of complete remission in a patient with advanced hepatocellular carcinoma: a case report.
Sun C; Ma X; Jiang L; Zhu X
Anticancer Drugs; 2024 Apr; 35(4):358-361. PubMed ID: 38385998
[TBL] [Abstract][Full Text] [Related]
28. Radiosensitization by combining an aurora kinase inhibitor with radiotherapy in hepatocellular carcinoma through cell cycle interruption.
Lin ZZ; Chou CH; Cheng AL; Liu WL; Chia-Hsien Cheng J
Int J Cancer; 2014 Jul; 135(2):492-501. PubMed ID: 24375034
[TBL] [Abstract][Full Text] [Related]
29. In vitro studies of H520 cell cycle and apoptosis by anlotinib combined with radiotherapy.
Guo L; Zhang L; Guan Y; Li Y; Zhang C; Guo Q
Thorac Cancer; 2021 Mar; 12(5):593-602. PubMed ID: 33438349
[TBL] [Abstract][Full Text] [Related]
30. Anlotinib inhibits the progress of colorectal cancer cells by antagonizing VEGFR/JAK2/STAT3 axis.
Jia ZX; Zhang Z; Li Z; Li A; Xie YN; Wu HJ; Yang ZB; Zhang HM; Zhang XM
Eur Rev Med Pharmacol Sci; 2021 Mar; 25(5):2331-2343. PubMed ID: 33755971
[TBL] [Abstract][Full Text] [Related]
31. Synergistic Antitumor Effects of Anlotinib Combined with Oral 5-Fluorouracil/S-1 via Inhibiting Src/AKT Signaling Pathway in Small-Cell Lung Cancer.
Xia X; Pi W; Lan Y; Wu X; Lv D; Meng Y; Yang H; Wang W
Anal Cell Pathol (Amst); 2022; 2022():4484211. PubMed ID: 35757014
[TBL] [Abstract][Full Text] [Related]
32. Directly targeting c-Myc contributes to the anti-multiple myeloma effect of anlotinib.
Cao Y; Shan H; Liu M; Liu J; Zhang Z; Xu X; Liu Y; Xu H; Lei H; Yu M; Zhang X; Liu W; Bu Z; Fang Z; Ji Y; Yan H; Gu W; Wu Y
Cell Death Dis; 2021 Apr; 12(4):396. PubMed ID: 33854043
[TBL] [Abstract][Full Text] [Related]
33. Anlotinib Inhibits Cell Proliferation, Migration and Invasion via Suppression of c-Met Pathway and Activation of ERK1/2 Pathway in H446 Cells.
Tang X; Zheng Y; Jiao D; Chen J; Liu X; Xiong S; Chen Q
Anticancer Agents Med Chem; 2021; 21(6):747-755. PubMed ID: 32682383
[TBL] [Abstract][Full Text] [Related]
34. Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2, PDGFRβ and FGFR1.
Lin B; Song X; Yang D; Bai D; Yao Y; Lu N
Gene; 2018 May; 654():77-86. PubMed ID: 29454091
[TBL] [Abstract][Full Text] [Related]
35. PI3K inhibitor impairs tumor progression and enhances sensitivity to anlotinib in anlotinib-resistant osteosarcoma.
Chen C; Guo Y; Huang Q; Wang B; Wang W; Niu J; Lou J; Xu J; Ren T; Huang Y; Guo W
Cancer Lett; 2022 Jun; 536():215660. PubMed ID: 35318116
[TBL] [Abstract][Full Text] [Related]
36. Complete pathological response with diabetic ketoacidosis to the combination of sintilimab and anlotinib in an unresectable hepatocellular carcinoma patient: a case report.
Fu L; Chen P; Wang S; Liu W; Chen Z; Chen H; Fu Z
Anticancer Drugs; 2022 Jan; 33(1):e741-e746. PubMed ID: 34338239
[TBL] [Abstract][Full Text] [Related]
37. Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical Trial.
Han B; Li K; Wang Q; Zhang L; Shi J; Wang Z; Cheng Y; He J; Shi Y; Zhao Y; Yu H; Zhao Y; Chen W; Luo Y; Wu L; Wang X; Pirker R; Nan K; Jin F; Dong J; Li B; Sun Y
JAMA Oncol; 2018 Nov; 4(11):1569-1575. PubMed ID: 30098152
[TBL] [Abstract][Full Text] [Related]
38. Anlotinib inhibits the proliferation and induces apoptosis by inactivating the AKT pathway in androgen receptor-negative prostate cancer cells.
Xu Y; Zheng J; Ye ZY
Neoplasma; 2022 Sep; 69(5):1119-1128. PubMed ID: 36004650
[TBL] [Abstract][Full Text] [Related]
39. A novel multi-target tyrosine kinase inhibitor anlotinib combined with irinotecan has in-vitro anti-tumor activity against human small-cell lung cancer.
Li H; Liu Y; Liu X; Zhao D; Liu J; Cheng Y
Anticancer Drugs; 2020 Nov; 31(10):1057-1064. PubMed ID: 32694423
[TBL] [Abstract][Full Text] [Related]
40. Anlotinib exerts anti-cancer efficiency on lung cancer stem cells in vitro and in vivo through reducing NF-κB activity.
Li Z; Tian J; Du L; Gao Y; Wang Y; You F; Wang L
J Cell Mol Med; 2021 Jun; 25(12):5547-5559. PubMed ID: 33955683
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
